Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S (MRK) Stock Price & Analysis

7 Followers

MRK Stock Chart & Stats

CA$32.62-CA$0.02(-0.06%)

At close: Nov 12 4:00 PM EST

Day’s Range: CAD 32.62 - CAD 33.02
52-Week Range: CAD 23.61 - CAD 34.90
Previous Close: CAD 32.64
Volume: N/A
Average Volume (3M): 22.30K
Market Cap: CAD 517.18B
Enterprise Value: CAD 142.67B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): 149.2
Beta: 0.75
Next Earnings: Feb 02, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Sep 15, 2026
Dividend Yield: 2.34%

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S News

Moderna says Marlborough expected to become global supply site for intismeran

The company said, “Manufacturing is a core component of Moderna’s (MRNA) integrated mRNA platform, supporting commercial vaccine supply, strategic partnerships and the potential launch of individualized cancer therapies. Manufacturing operations

19h agoMRK MRNA

Surrozen price target raised to $80 from $42 at Guggenheim

Guggenheim raised the firm’s price target on Surrozen (SRZN) to $80 from $42 and keeps a Buy rating on the shares. Following Merck’s (MRK) full disclosure of Remigromig in DME

20h agoMRK SRZN

Merck reports Phase 2b MK-6024-013 trial met primary efficacy endpoint

Merck (MRK) announced the presentation of “positive” results from the company’s Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide, an investigational

3d agoMRK 6MK

Adagene completes enrollment in muzastotug trial

Adagene (ADAG) announced completion of enrollment in its randomized Phase 2 dose-optimization trial of muzastotug, a masked, anti-CTLA-4 SAFEbody, in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda, in patients with

3d agoMRK ADAG

Leerink downgraded Halozyme to Market Perform on limited upside potential

As previously reported, Leerink downgraded Halozyme (HALO) to Market Perform from Outperform with a price target of $117, up from $110, driven by financial model revisions, changing the discount rate

6d agoMRK HALO

Merck initiates Phase 3 study of Ohtuvayre

Merck (MRK) announced the initiation of ENHANCE-3, a Phase 3 randomized clinical trial evaluating Ohtuvayre (ensifentrine) for the prevention of chronic obstructive pulmonary disease exacerbations in adult patients receiving standard

1w agoMRK 6MK

Merck downgraded to Hold from Buy at DZ Bank

DZ Bank analyst Elmar Kraus downgraded Merck (MRK) to Hold from Buy with a $153 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial

1w agoMRK 6MK

Merck price target raised to $140 from $125 at Freedom Broker

Freedom Broker raised the firm’s price target on Merck (MRK) to $140 from $125 and keeps a Hold rating on the shares. The firm raised its valuation multiple with investors

1w agoMRK 6MK

Securitize expands onchain U.S. stock offering to 25 equities

Securitize (SECZ) announced the expansion of Securitize Stocks with 13 additional U.S. equities, bringing the total offering to 25 stocks available onchain for eligible investors in the U.S., E.U. and

1w agoCRM DIS

Merck price target raised to $155 from $145 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Merck (MRK) to $155 from $145 and keeps a Neutral rating on the shares. Merck delivered a solid ESMO showing and better-than-expected

1w agoMRK 6MK

Merck: Emerging Oncology Pipeline Encouraging but Still Early; Risk/Reward Balanced with Price Target Maintained at $145

Citi analyst Geoff Meacham maintained a Hold rating on Merck & Company yesterday and set a price target of $145.00. Geoff Meacham has given his Hold rating due to a

2w agoMRK 6MK

Nuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs (NASDAQ: NVCT)

WSW, NY, October 26th, 2026, FinanceWire Tumors shrank in 22 of 27 patients treated with NXP200 alone. The results give Nuvectis a clinical foundation in a drug class that has

2w agoMRK PFE

Merck: Emerging Immunology Strength and HS Execution Support Unchanged $160 Price Target and Buy Rating

Merck & Company, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Asad Haider from Goldman Sachs maintained a Buy rating on the stock and has

1M agoMRK 6MK

Merck Buy Rating Reiterated as Compelling Tulisokibart Data and Diversified Pipeline Support Outlook; $170 Price Target Maintained

Merck & Company, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital maintained a Buy rating on the stock and has

1M agoMRK 6MK

MRK FAQ

What was Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s price range in the past 12 months?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S lowest stock price was C$23.61 and its highest was C$34.90 in the past 12 months.

What is Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s market cap?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s market cap is C$517.18B.

When is Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s earnings last quarter?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S released its earnings results on Oct 29, 2026. The company reported C$2.862 earnings per share for the quarter.

Is Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S pay dividends?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S pays a dividend of C$0.189 which represents an annual dividend yield of 2.34%. See more information on Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S dividends here

What is Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s EPS estimate?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S have?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S has 2,467,171,600 shares outstanding.

What happened to Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S’s price movement after its last earnings report?

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S reported an EPS of C$2.862 in its last earnings report. Following the earnings report the stock price went up 3.412%.

Which hedge fund is a major shareholder of Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S?

Currently, no hedge funds are holding shares in TSE:MRK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S (MRK) Earnings & Revenues

Historic Earnings Reports

MRK Earnings Call

Q3 2026

Earnings Call SentimentPositive

The call was strongly positive. Merck reported revenue growth, raised full-year revenue and EPS guidance, delivered strong performance from KEYTRUDA, WELIREG, Gardasil, WINREVAIR, and animal health, and highlighted multiple positive clinical and regulatory milestones. The company also acknowledged meaningful challenges, including generic and loss-of-exclusivity headwinds expected in 2027, lower United States CAPVAXIVE sales, purchase-timing reversals, higher operating expenses, the QLEX European injunction, and the withdrawal of the ifinatamab deruxtecan application. Overall, the highlights significantly outweighed the lowlights, with management expressing confidence in the pipeline and long-term growth beyond the KEYTRUDA LOE period.

View all TSE:MRK earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	10	6	6
Technical Analysis	1	6	3
Moving Averages	9	0	3

Technical Analysis >

Similar Stocks

Stocks similar to TSE:MRK
Company	Price & Change	Follow
TSE:ROGRoche Holding Ltd CAD Hedged CIBC CDR
TSE:NVSNovartis AG CAD Hedged CIBC CDR
TSE:PFEPfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S
TSE:ABBVAbbVie, Inc. CDR (CAD Hedged)
TSE:JNJJohnson & Johnson Shs

Compare TSE:MRK Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

MRK Stock Chart & Stats

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S News

Moderna says Marlborough expected to become global supply site for intismeran

Surrozen price target raised to $80 from $42 at Guggenheim

Merck reports Phase 2b MK-6024-013 trial met primary efficacy endpoint

Adagene completes enrollment in muzastotug trial

Leerink downgraded Halozyme to Market Perform on limited upside potential

Merck initiates Phase 3 study of Ohtuvayre

Merck downgraded to Hold from Buy at DZ Bank

Merck price target raised to $140 from $125 at Freedom Broker

Securitize expands onchain U.S. stock offering to 25 equities

Merck price target raised to $155 from $145 at Cantor Fitzgerald

Merck: Emerging Oncology Pipeline Encouraging but Still Early; Risk/Reward Balanced with Price Target Maintained at $145

Nuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs (NASDAQ: NVCT)

Merck: Emerging Immunology Strength and HS Execution Support Unchanged $160 Price Target and Buy Rating

Merck Buy Rating Reiterated as Compelling Tulisokibart Data and Diversified Pipeline Support Outlook; $170 Price Target Maintained

MRK FAQ

Company Description

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S

Merck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S (MRK) Earnings & Revenues

MRK Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive